Sin-ho Jung,

Department:
Biostatistics and Bioinformatics

Email Address:
sinho.jung@duke.edu

Address:
DUMC Box 2721

Durham, NC 27710

Telephone:
9196688658

Research Interests:
Design of Clinical Trials
Survival Analysis
Longitudinal Data Analysis
Clustered Data Analysis
ROC Curve Analysis
Design and Analysis of Microarray Studies

Publications:
2002 -- Pubmed # 11846853 -- Ahn C, Jung SH, Donner A. Application of an adjusted chi2 statistic to site-specific data in observational dental studies. J Clin Periodontol. 2002 Jan;29(1):79-82.

2001 -- Pubmed # 11514038 -- Jung SH, Carey M, Kim KM. Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials. 2001 Aug;22(4):367-72.

2001 -- Pubmed # 11696735 -- Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol. 2001 Dec;166(6):2198-201.

2001 -- Pubmed # 11473371 -- Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001 Aug;77(4):237-42.

2000 -- Pubmed # 10953139 -- Koch MO, Foster RS, Bell B, Beck S, Cheng L, Parekh D, Jung SH. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol. 2000 Sep;164(3 Pt 1):749-53.

1999 -- Pubmed # 10214003 -- Jung SH. Rank tests for matched survival data. Lifetime Data Anal. 1999;5(1):67-79.

1996 -- Pubmed # 8608504 -- Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, Creagan ET, Goldberg RM, Marschke RF Jr. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer. 1996 Apr 1;77(7):1284-91.

1995 -- Pubmed # 7595738 -- Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995 Nov;13(11):2776-83.

1995 -- Pubmed # 7541157 -- Jett JR, Kirschling RJ, Jung SH, Marks RS. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol. 1995 Jun;22(3 Suppl 6):75-7.

1995 -- Pubmed # 8552898 -- Jung SH, Wieand S, Cha SS. A statistic for comparing two correlated markers which are prognostic for time to an event. Stat Med. 1995 Oct 30;14(20):2217-25.

1994 -- Pubmed # 8168039 -- Ingle JN, Foley JF, Mailliard JA, Krook JE, Hartmann LC, Jung SH, Veeder MH, Gesme DH Jr, Hatfield AK, Goldberg RM. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer. 1994 May 1;73(9):2337-43.